Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5765145 | 0.87 | HTR2C (0.51) | HTR2CHTR2BHTR2ANOTUMGAA | |
| SCHEMBL6946819 | 0.79 | HTR2C (0.56) | HTR2CHTR2BSRD5A1HTR2ANOTUM | |
| SCHEMBL6947978 | 0.79 | SRD5A1 (0.54) | HTR2CHTR2BSRD5A1HTR2ANOTUM | |
| SCHEMBL31061020 | 0.77 | NOTUM (0.51) | HTR2CHTR2BSRD5A1HTR2ANOTUM | |
| SCHEMBL3723794 | 0.77 | OPRM1 (0.65) | HTR2CHTR2BHTR2ANOTUMGAA | |
| SCHEMBL14698875 | 0.77 | NOTUM (0.63) | SRD5A1NOTUMOPRL1OPRM1OPRK1 | |
| SCHEMBL10652419 | 0.76 | HTR2C (0.71) | HTR2CHTR2BSRD5A1HTR2AGAA | |
| SCHEMBL12638317 | 0.76 | HTR2C (0.71) | HTR2CHTR2BSRD5A1HTR2AGAA | |
| SCHEMBL10653852 | 0.75 | HTR2C (0.69) | HTR2CHTR2BSRD5A1HTR2AGAA | |
| SCHEMBL10671459 | 0.73 | HTR2C (0.57) | HTR2CHTR2BSRD5A1HTR2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999747-B1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-23 | — | — | EP | claimed |
| EP-0880520-B1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-16 | — | — | EP | claimed |
| US-6514912-B1 | Use of benzo[C]quinolizine derivatives as plant growth regulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-04 | — | — | US | claimed |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-29 | — | — | US | claimed |
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-22 | — | — | US | claimed |
| US-6303622-B1 | FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2001-10-16 | — | — | US | claimed |
| EP-0999747-A1 | USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2000-05-17 | — | — | EP | claimed |
| WO-1999005913-A1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1999-02-11 | — | — | WO | claimed |
| EP-0880520-A1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1998-12-02 | — | — | EP | claimed |
| WO-1997029107-A1 | BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5α-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1997-08-14 | — | — | WO | claimed |
| US-6555549-B2 | Useful in treating acne, baldness, prostatic cancer and hypertrophy in men and hirsutism in women | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-29 | — | — | US | disclosed |
| EP-0999747-B1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-23 | — | — | EP | disclosed |
| US-6552034-B2 | Cyclization of a silylated butadiene reacted with a 2-oxo-1,2,3,4-tetrahydroquinoline; acne; alopecia; prostatic cancer and hypertrophy; hirsutism in women; skin and glandular disorders; anticarcinogenic agents | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-22 | — | — | US | disclosed |
| EP-0880520-B1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-16 | — | — | EP | disclosed |
| US-6514912-B1 | Use of benzo[C]quinolizine derivatives as plant growth regulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-04 | — | — | US | disclosed |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-29 | — | — | US | disclosed |
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-22 | — | — | US | disclosed |
| US-6303622-B1 | FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2001-10-16 | — | — | US | disclosed |
| EP-0880520-A1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029107-A1 | BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5α-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | HTR2C 531/4885HTR2B 1556/4885SRD5A1 8/4885 |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | HTR2C 531/4885HTR2B 1556/4885SRD5A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.